Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer, will participate in a fireside chat at The JMP Securities Hematology Summit on Tuesday, December 15, 2020 at 2:00 PM ET.

Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit

MENLO PARK, Calif. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Bastiano Sanna, Ph.D., to its Board of Directors. Dr. Sanna brings significant expertise in advancing research, development and manufacturing of cell therapies. He currently serves as Executive Vice President and Chief of Cell and Genetic Therapies at Vertex Pharmaceuticals Incorporated.

Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors

MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results for the third quarter ended September 30, 2020.

Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update

MENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Don Healey, Ph.D., as Chief Technology Officer. Dr. Healey will lead the development of Adicet's genetically-modified T cell therapies for clinical development and commercialization, including manufacturing, viral vector operations and analytics.

Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer

Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin's lymphoma Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin's lymphoma

Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy

MENLO PARK, Calif. and BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer of Adicet Bio, and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer of Adicet Bio, will participate in a fireside chat at the Jefferies Cell Therapy Summit on Monday, October 5, 2020 at 2:30 PM ET.

Adicet Bio to Present at the Jefferies Cell Therapy Summit

MENLO PARK, Calif. and BOSTON, Sept.  22, 2020  (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced today that it has determined not to proceed with its proposed public offering of 4,500,000 shares of its common stock previously announced on September 21, 2020. The Company believes that current market conditions are not conducive to an offering on terms that would be in the best interests of its current stockholders. 

Adicet Bio, Inc. Determines Not to Proceed with Public Offering of Common Stock

MENLO PARK, Calif. and BOSTON, Sept.  21, 2020  (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that it has commenced an underwritten public offering of 4,500,000 shares of its common stock. Adicet also intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering are to be sold by Adicet. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock

MENLO PARK, Calif. and BOSTON, Sept.  18, 2020  (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that on September 17, 2020, the Compensation Committee of Adicet’s Board of Directors granted non-qualified stock options of 195,898 shares of its common stock to Nick Harvey pursuant to an Inducement Non-Qualified Stock Option Agreement (the “Harvey Stock Option”). On September 16, 2020, Adicet announced the appointment of Mr. Harvey as Chief Financial Officer responsible for leading the company’s financial strategy and management of activities related to accounting, capital markets and business operations.

Adicet Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

MENLO PARK, Calif. and BOSTON, Sept.  16, 2020  (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq:  ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Nick Harvey as Chief Financial Officer. Mr. Harvey will be responsible for leading the company’s financial strategy and management of activities related to accounting, capital markets and business operations.

Adicet Bio Appoints Nick Harvey as Chief Financial Officer

MENLO PARK, Calif., Sept.  15, 2020  (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq:  ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer of Adicet Bio, will present at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 8:40 AM ET.

Adicet Bio to Present at the Cantor Virtual Global Healthcare Conference

News for Adicet Bio, Inc. Stock (ACET)